home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

Impact China IV: Pharmaceutical R&D Global Summit

  March 13, 2008  
Oraganized by Strategic Research Institute, Beijing, China
May 4-6, 2008

As China continues its unprecedented growth, the question is no longer are you working in China but how are you working in China.  The Chinese market continues to mature and now is the time to fully develop a decisive stratagem for accessing the market and realizing the benefits China offers.

Impact China has grown along with the market with its comprehensive coverage of vital issues and progressive business strategies.  2008 is no exception as special focus will be given to your essential interests and paramount concerns, including:

  • Toxicology Outsourcing: The Growing Demand for Niche Specialties in China
  • Conducting Clinical Trials in China
  • Collaborations & Partnerships
  • Reforms & Regulations
  • CROS and Outsourcing to China
  • Investors: Perspectives & Opportunities
  • Generics & Quality Assurance
  • Novel Advancements and Developments Originating in China
  • Working in China: Options for Getting Business Done
  • Incorporating Traditional Chinese Medicine into your Pipeline

Only at Impact China will you also find dedicated sessions covering:

  • Competitive Models of Retail Pharmacy in China
  • Innovations in the Global Economy
  • Chinese SFDA and Global Drug Development – Quality, Science and Speed

Policy and Regulations: Reactions on the Current Landscape:  This unprecedented session featuring policy makers from the SFDA, RDPAC and the Ministry of Public Health, will address key regulatory issues along with insight for improving speed and performance. 

Organized by: Strategic Research Institute
Invited Speakers:
  • Dr. Zhiqiang An, Merck Research Laboratories
  • Steven Bottomley, Mayer Brown
  • Sean Caffey, M.D., M.B.A., Biomimetic MicroElectronic Systems NSF Engineering Research Center, University of Southern California, CalTech and UC Santa Cruz
  • Jason Chen, Cardinal Health
  • Norman Chen, Fidelity Asia Ventures
  • Shaoyu Chen, Amgen
  • Vivian Chen, RDPAC
  • Zhengming "Jimmy" Chen, Ph.D., DOV Pharmaceutical, Inc.
  • Tao Cheng, M.D., University of Pittsburgh School of Medicine/ University of Pittsburgh Cancer Institute
  • Matthew Chervenak, General Biologic
  • Karen Chu, Parexel
  • Paul Dai, M.D., Novartis China
  • Hongkui Deng, Peking University
  • Mark Engel, Excel PharmaStudies
  • Zack Fang, ESI
  • Jun Gu, Ph.D., M.D., Wadsworth Center, USA
  • Yun He, Roche
  • Dr. Ruediger Herrmann, Mayer Brown
  • Min Irwin, M.D., Ph.D., Bayer HealthCare Company Ltd.
  • Eita Kitayama, Synta Pharmaceuticals Corp.
  • George Lankas, Ph.D., Amicus Therapeutics, Inc.
  • Hai Chao Lei, Ministry of Public Health
  • Jifeng Li, Shanghai Anbison Lab. Ltd. Co.
  • Zili Li, M.D. MPH, Merck & Co, Inc.
  • Hun-Chi Lin, Ph.D., Global TransBiotech, Inc. (GTB)
  • Allan (Riting) Liu, Ph.D., M.B.A., Wanbang Biopharm Co. Ltd./ Fosun Pharmaceutical (Group) Co., Ltd.
  • Janet Lu, BS, MDS China
  • Ronald J.Marler, DVM, Ph.D., Bridge Laboratories
  • D.Thomas Oakley, Bridge Laboratories
  • Xuetao Pei, Beijing Institute of Transfusion Medicine
  • Sofie Qiao, Ph.D., LEAD Therapeutics
  • Carl Ren, China Monitor
  • Jin Ren, M.D., Ph.D., Center for Drug Safety Evaluation & Research Shanghai Institute of Materia Medica Chinese Academy of Sciences
  • Hironobu Saito, Ph.D., Daiichi Sankyo
  • James J. Shen, Pharma China/ Wicon International Group
  • Ray Shen, Beijing Elite
  • Lai-Lee Tan, Quintiles
  • Maria Song, Ph.D., M.D., VPSCRO Global Corp. Member of Venturepharm Group
  • Dr. Xiaoxiong "Jim" Wei, Medpace
  • Jimmy Wei, Ph.D., M.B.A., Hutchison MediPharma
  • Patrick C.K. Wong, Mayer Brown
  • James Xin, Beijing Elite
  • Tianpei Xie, M.D., Ph.D., Shanghai Standard Biotech Co. Ltd.
  • Jia Qi Xu, SFDA
  • Steve Q. Yang, Pfizer Global Research & Development
  • Cathy Yang, RDPAC
  • Zhimin Yang, M.D., SFDA, Center for Drug Evaluation
  • Dan Zhang, Fountain Medical Development Ltd.
  • Danyi Zhang, M.D., VitalStrategic Research Institute
  • Kehong Zhang, M.D., Ph.D., Shanghai Standard Biotech Co. Ltd.
Deadline for Abstracts: Sea Turtle Showcase - abstract deadline April 15, 2008


E-mail: acrow@alm.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.